CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $119.84M, above the global median of $16.24M
- PositionOperating margin is 50%, higher than 95% of its Biotechnology peers (median -34.2%)
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
660.56MUSDvs all stocks (USD)
Trailing P/E
3.88xvs Biotechnology peers
Revenue (TTM)
400.05MUSDvs all stocks (USD)
Profit Margin
45.25%vs Biotechnology peers
Beta
1.48xvs all stocks
52-Week Change
-23.03%vs all stocks
Market Capitalization
660.56MUSDvs all stocks (USD)
Enterprise Value
629.89MUSDvs all stocks (USD)
Trailing P/E
3.88xvs Biotechnology peers
Forward P/E
24.06xvs Biotechnology peers
PEG Ratio
0.0776xvs Biotechnology peers
Price to Sales (TTM)
1.65xvs Biotechnology peers
Price to Book (MRQ)
1.51xvs Biotechnology peers
Enterprise to Revenue
1.57xvs Biotechnology peers
Enterprise to EBITDA
2.75xvs Biotechnology peers
Gross Margin
82.50%vs Biotechnology peers
Profit Margin
45.25%vs Biotechnology peers
Operating Margin
49.96%vs Biotechnology peers
Return on Assets (TTM)
26.40%vs Biotechnology peers
Return on Equity (TTM)
65.59%vs Biotechnology peers
Revenue (TTM)
400.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.29USDUpdated Jul 18, 2026Quarterly Revenue Growth
226.10%vs Biotechnology peers
Gross Profit (TTM)
367.50MUSDvs all stocks (USD)
EBITDA (TTM)
229.63MUSDvs all stocks (USD)
Net Income (TTM)
180.02MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
87.00%vs Biotechnology peers
Operating Cash Flow (TTM)
197.69MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
119.84MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
311.71MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
35.96MUSDFY2025 · Dec 31, 2025Gross Profit
275.75MUSDFY2025 · Dec 31, 2025Operating Income
150.14MUSDvs all stocks (USD)
Pre-tax Income
150.02MUSDFY2025 · Dec 31, 2025Income Tax Expense
-13.04MUSDFY2025 · Dec 31, 2025Net Income
163.06MUSDFY2025 · Dec 31, 2025EBIT
152.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
168.54MUSDFY2025 · Dec 31, 2025Research & Development
19.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
106.27MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.25USDFY2025 · Dec 31, 2025EPS (Diluted)
2.04USDFY2025 · Dec 31, 2025Basic Shares Outstanding
72.03MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
72.03MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
163.06MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
988.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
81.53MUSDFY2025 · Dec 31, 2025Free Cash Flow
79.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
145.82MUSDFY2025 · Dec 31, 2025Interest Paid
17.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
163.06MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.55MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-25.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
7.28MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-90.92MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.33MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.79MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.26MUSDFY2025 · Dec 31, 2025Net Acquisitions
-308.51MUSDFY2025 · Dec 31, 2025Purchase of Investments
-52.95MUSDFY2025 · Dec 31, 2025Sale of Investments
55.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-308.43MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
150.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-8.09MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
232.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
78.40MSharesUpdated Jul 18, 2026Float Shares
66.53MSharesUpdated Jul 18, 2026Shares Short
14.93MSharesUpdated Jul 18, 2026Short Ratio
9.53daysvs all stocks
Short % of Shares Outstanding
19.29%vs all stocks
% Held by Insiders
7.53%vs all stocks
% Held by Institutions
54.72%vs all stocks
Total Cash (MRQ)
178.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.27USDUpdated Jul 18, 2026Total Debt (MRQ)
147.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3373xvs Biotechnology peers
Current Ratio (MRQ)
2.98xvs Biotechnology peers
Book Value per Share (MRQ)
5.58USDUpdated Jul 18, 2026Total Assets
826.14MUSDvs all stocks (USD)
Total Current Assets
367.05MUSDFY2025 · Dec 31, 2025Total Liabilities
420.83MUSDFY2025 · Dec 31, 2025Total Non-current Assets
459.09MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
246.57MUSDFY2025 · Dec 31, 2025Total Current Liabilities
174.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
144.84MUSDFY2025 · Dec 31, 2025Other Short-term Investments
3.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
171.23MUSDFY2025 · Dec 31, 2025Inventory
29.72MUSDFY2025 · Dec 31, 2025Accounts Payable
7.88MUSDFY2025 · Dec 31, 2025Short-term Debt
1.45MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.02MUSDFY2025 · Dec 31, 2025Long-term Debt
147.47MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
99.10MUSDFY2025 · Dec 31, 2025Common Stock (Book)
79.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-176.57MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
405.31MUSDvs all stocks (USD)
52-Week Low
6.13USDUpdated Jul 18, 202652-Week High
14.96USDUpdated Jul 18, 202652-Week Change
-23.03%vs all stocks
Beta
1.48xvs all stocks
50-Day MA
8.29USDUpdated Jul 18, 2026200-Day MA
8.81USDUpdated Jul 18, 2026Avg 10-Day Volume
837.66KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.35MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
2.17USDUpdated Jul 18, 2026Other Income / Expense
-1.19MUSDFY2025 · Dec 31, 20259 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Where is this company structurally exposed?
Share Dilution
Its share count has grown over six years, with more waiting in options.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 50%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.50Industry median: -0.34Industry P95: 0.41Peers compared: 261
Profit margin is 45.2%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.45Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 65.6%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.66Industry median: -0.22Industry P95: 0.23Peers compared: 261
Return on assets is 26.4%, higher than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: 0.26Industry median: -0.20Industry P95: 0.15Peers compared: 261
P/E ratio is 3.88×, lower than 95% of its Biotechnology peers (median 32.39×)Notable
P/E ratio: 3.88Industry median: 32.39Industry P5: 5.49Peers compared: 261
Financial Health
Altman Z-Score 1.91: grey zoneSignificant
Altman Z-Score: 1.91
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $119.84M, above the global median of $16.24MNotable
Levered free cash flow (USD): 119,837,056Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
XD Inc.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Aurinia Pharmaceuticals Inc.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels